| Literature DB >> 33801561 |
Sun Young Lee1, In Young Kim2, Min Beom Heo2, Jeong Hee Moon3, Jin Gyeong Son1, Tae Geol Lee1.
Abstract
Silica nanoparticles (SiO2 NPs) are commonly used in medical and pharmaceutical fields. Research into the cytotoxicity and overall proteomic changes occurring during initial exposure to SiO2 NPs is limited. We investigated the mechanism of toxicity in human liver cells according to exposure time [0, 4, 10, and 16 h (h)] to SiO2 NPs through proteomic analysis using mass spectrometry. SiO2 NP-induced cytotoxicity through various pathways in HepG2 cells. Interestingly, when cells were exposed to SiO2 NPs for 4 h, the morphology of the cells remained intact, while the expression of proteins involved in mRNA splicing, cell cycle, and mitochondrial function was significantly downregulated. These results show that the toxicity of the nanoparticles affects protein expression even if there is no change in cell morphology at the beginning of exposure to SiO2 NPs. The levels of reactive oxygen species changed significantly after 10 h of exposure to SiO2 NPs, and the expression of proteins associated with oxidative phosphorylation, as well as the immune system, was upregulated. Eventually, these changes in protein expression induced HepG2 cell death. This study provides insights into cytotoxicity evaluation at early stages of exposure to SiO2 NPs through in vitro experiments.Entities:
Keywords: cytotoxicity; label-free quantification; mass spectrometry; proteomic analysis; silica nanoparticles
Year: 2021 PMID: 33801561 PMCID: PMC8000044 DOI: 10.3390/biom11030375
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1(A) Transmission electron microscopic image and (B) FT-IR spectrum of 20 nm SiO2 NPs before culturing with HepG2 cells.
Characterization of SiO2 NPs (Mean ± SD, n = 3).
| Characterization Techniques | 20 nm SiO2 NPs |
|---|---|
| TEM (nm) | 19.6 ± 0.5 |
| DLS (nm) | 21.0 ± 0.1 |
| Polydispersity Index | 0.139 ± 0.011 |
| Zeta potential (mV) | −34.2 ± 3.5 |
Figure 2Cell viability assay. (A) The morphologies of HepG2 cells using bright-field microscopy. The upper images are HepG2 cells without SiO2 NPs, and the lower images are SiO2 NP (30 μg/mL)-treated groups exposed for 0, 4, 10, and 16 h. (B) Lactate dehydrogenase (LDH) leakage assay of SiO2 NP-treated groups with increasing exposure time. Data shown are mean ± standard deviation of three independent experiments. Asterisks indicate effects in comparison to the 0 h control group (* p < 0.05, ** p < 0.005).
Figure 3Label-free quantification (LFQ)-based proteomic analysis of HepG2 cells in comparison with controls and SiO2 NP groups at each time point (4, 10, and 16 h). (A) Venn diagram of the quantified proteins after the treatment of SiO2 NPs for 4, 10, and 16 h. (B) Upregulated and downregulated proteins in HepG2 cells exposed to SiO2 NPs after 4, 10, and 16 h compared to their control groups.
Figure 4Protein–protein interaction networks (PPI) of differentially expressed proteins in HepG2 cells regulated by SiO2 NPs using a STRING algorithm. The color circles represent the cellular interaction with highest confidence (score ≥ 0.9) are shown. PPI of downregulated and upregulated proteins for (A,B) 4, (C,D) 10, and (E,F) 16 h groups.
Figure 5(A) Heatmap (with hierarchical cluster analysis) and (B) principal component analysis of the differentially expressed proteins from SiO2 NPs-treated HepG2 cells in increase of exposure time in comparison to the 0 h group. The filled circles of the same color represent four duplicates.
List of downregulated proteins from control and SiO2 NP groups of HepG2 cells by the exposure time associated with the biological pathway.
| Protein | Description | Fold Change Compared to 0 h Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Control (h) | SiO2 NPs (h) | |||||||
| 4 | 10 | 16 | 4 | 10 | 16 | |||
|
| ||||||||
| CARE | Cell cycle and apoptosis regulator protein 2 | 1.06 | 0.96 | 1.25 | 0.54 | 0.38 | 0.55 | 2.09 × 10−7 |
| VPS35 | Vacuolar protein sorting-associated protein 35 | 1.07 | 1.32 | 1.51 | 0.39 | 0.88 | 0.91 | 3.52 × 10−7 |
| DNM1L | Dynamin-1-like protein | 1.04 | 1.08 | 1.03 | 0.47 | 0.77 | 0.66 | 2.19 × 10−5 |
|
| ||||||||
| TPR | Nucleoprotein TPR | 1.06 | 1.14 | 1.12 | 0.39 | 0.52 | 0.57 | 1.32 × 10−9 |
| UBE2N | Ubiquitin-conjugating enzyme E2 N | 0.94 | 1.20 | 1.19 | 0.36 | 0.68 | 0.62 | 6.41 × 10−9 |
| PRKDC | DNA-dependent protein kinase catalytic subunit | 1.04 | 1.11 | 1.17 | 0.42 | 0.63 | 0.84 | 1.25 × 10−8 |
| MDC1 | Mediator of DNA damage checkpoint protein 1 | 0.93 | 1.00 | 1.11 | 0.39 | 0.50 | 0.54 | 1.48 × 10−8 |
| PCH2 | Pachytene checkpoint protein 2 homolog | 1.11 | 1.35 | 1.20 | 0.18 | 0.56 | 0.78 | 6.76 × 10−8 |
| PIP30 | PSME3-interacting protein | 1.00 | 0.88 | 0.82 | 0.47 | 0.44 | 0.44 | 6.84 × 10−8 |
| CDK1 | Cyclin-dependent kinase 1 | 1.01 | 0.94 | 1.13 | 0.38 | 0.45 | 0.45 | 8.97 × 10−8 |
| NSUN2 | RNA cytosine C(5)-methyltransferase NSUN2 | 1.02 | 0.85 | 0.94 | 0.45 | 0.38 | 0.41 | 1.14 × 10−7 |
| RCC2 | Protein RCC2 | 1.05 | 1.09 | 1.14 | 0.44 | 0.71 | 0.78 | 1.23 × 10−7 |
| MARE1 | Microtubule-associated protein RP/EB family member 1 | 1.00 | 1.12 | 1.26 | 0.31 | 0.75 | 0.68 | 6.67 × 10−7 |
| NU107 | Nuclear pore complex protein Nup107 | 0.97 | 0.97 | 1.18 | 0.44 | 0.67 | 0.66 | 1.08 × 10−6 |
| MRE11 | Double-strand break repair protein MRE11 | 1.02 | 1.20 | 1.47 | 0.41 | 0.52 | 0.72 | 1.11 × 10−6 |
| PSD13 | 26S proteasome non-ATPase regulatory subunit 13 | 1.04 | 0.82 | 0.86 | 0.47 | 0.58 | 0.50 | 1.82 × 10−6 |
| PTN11 | Tyrosine-protein phosphatase non-receptor type 11 | 1.10 | 1.24 | 1.16 | 0.48 | 0.76 | 0.60 | 4.69 × 10−6 |
| PCNA | Proliferating cell nuclear antigen | 1.07 | 1.01 | 1.35 | 0.37 | 0.61 | 0.74 | 1.08 × 10−5 |
| TP53B | TP53-binding protein 1 | 0.67 | 1.07 | 0.94 | 0.18 | 0.32 | 0.44 | 4.89 × 10−5 |
| ZW10 | Centromere/kinetochore protein zw10 homolog | 0.90 | 1.13 | 0.84 | 0.25 | 0.78 | 0.96 | 8.63 × 10−3 |
|
| ||||||||
| THOC4 | THO complex subunit 4 | 0.99 | 0.99 | 1.03 | 0.39 | 0.55 | 0.56 | 1.08 × 10−12 |
| NUCKS | Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 | 0.98 | 1.03 | 1.12 | 0.23 | 0.36 | 0.48 | 2.71 × 10−11 |
| MCM6 | DNA replication licensing factor MCM6 | 1.12 | 0.96 | 1.31 | 0.32 | 0.47 | 0.58 | 7.11 × 10−11 |
| DHX9 | ATP-dependent RNA helicase A | 1.05 | 1.16 | 1.13 | 0.44 | 0.57 | 0.65 | 4.08 × 10−8 |
| MCM3 | DNA replication licensing factor MCM3 | 1.03 | 1.06 | 1.04 | 0.49 | 0.68 | 0.74 | 5.87 × 10−8 |
| RIR1 | Ribonucleoside-diphosphate reductase large subunit | 0.98 | 1.19 | 1.16 | 0.43 | 0.84 | 0.71 | 5.66 × 10−7 |
| RBM14 | RNA-binding protein 14 | 1.15 | 0.97 | 1.08 | 0.38 | 0.44 | 0.60 | 8.30 × 10−7 |
| RFA1 | Replication protein A 70 kDa DNA-binding subunit | 1.05 | 1.16 | 1.10 | 0.49 | 0.81 | 0.63 | 6.92 × 10−6 |
| DUT | Deoxyuridine 5′-triphosphate nucleotidohydrolase | 1.20 | 1.07 | 1.44 | 0.71 | 0.24 | 0.35 | 7.00 × 10−6 |
| NP1L1 | Nucleosome assembly protein 1-like 1 | 1.00 | 1.06 | 1.03 | 0.47 | 0.86 | 0.73 | 1.79 × 10−5 |
| DPOE3 | DNA polymerase epsilon subunit 3 | 1.10 | 0.89 | 1.10 | 0.56 | 0.37 | 0.46 | 5.71 × 10−5 |
| PRI2 | DNA primase large subunit | 0.87 | 1.03 | 1.06 | 0.48 | 0.62 | 0.76 | 1.14 × 10−4 |
| PURA | Transcriptional activator protein Pur-alpha | 1.44 | 0.99 | 1.34 | 0.45 | 0.78 | 0.76 | 2.18 × 10−4 |
| DPOLA | DNA polymerase alpha catalytic subunit | 0.97 | 1.13 | 1.27 | 0.49 | 0.60 | 0.68 | 5.98 × 10−4 |
|
| ||||||||
| PCBP1 | Poly(rC)-binding protein 1 | 0.92 | 0.88 | 0.94 | 0.38 | 0.51 | 0.60 | 2.55 × 10−11 |
| RBM25 | RNA-binding protein 25 | 0.97 | 0.95 | 1.07 | 0.49 | 0.43 | 0.45 | 6.81 × 10−10 |
| DDX42 | ATP-dependent RNA helicase DDX42 | 0.99 | 0.93 | 0.89 | 0.47 | 0.54 | 0.52 | 6.50 × 10−9 |
| U5S1 | 116 kDa U5 small nuclear ribonucleoprotein component | 1.01 | 0.98 | 0.82 | 0.38 | 0.54 | 0.58 | 4.54 × 10−8 |
| RUXE | Small nuclear ribonucleoprotein E | 0.91 | 1.92 | 2.19 | 0.26 | 1.17 | 1.39 | 1.55 × 10−7 |
| THOC3 | THO complex subunit 3 | 1.18 | 1.18 | 1.04 | 0.43 | 0.77 | 0.76 | 3.16 × 10−7 |
| LSM8 | U6 snRNA-associated Sm-like protein LSm8 | 1.09 | 1.22 | 1.42 | 0.24 | 0.79 | 0.88 | 4.85 × 10−7 |
| DDX46 | Probable ATP-dependent RNA helicase DDX46 | 0.96 | 1.16 | 1.08 | 0.45 | 0.68 | 0.66 | 5.52 × 10−7 |
| SR140 | U2 snRNP-associated SURP motif-containing protein | 1.08 | 1.04 | 0.91 | 0.58 | 0.62 | 0.46 | 6.44 × 10−7 |
| SPF27 | Pre-mRNA-splicing factor SPF27 | 1.05 | 0.94 | 1.28 | 0.36 | 0.65 | 0.80 | 7.71 × 10−7 |
| SNW1 | SNW domain-containing protein 1 | 1.01 | 1.08 | 1.06 | 0.31 | 0.73 | 0.69 | 6.98 × 10−5 |
| ROA3 | Heterogeneous nuclear ribonucleoprotein A3 | 0.95 | 1.04 | 1.00 | 0.49 | 0.85 | 0.70 | 9.25 × 10−5 |
| DDX23 | Probable ATP-dependent RNA helicase DDX23 | 0.94 | 1.22 | 1.03 | 0.44 | 0.66 | 0.62 | 1.41 × 10−4 |
| PR38B | Pre-mRNA-splicing factor 38B | 0.54 | 1.17 | 1.37 | 0.32 | 0.94 | 1.09 | 2.42 × 10−3 |
|
| ||||||||
| PFKAM | ATP-dependent 6-phosphofructokinase muscle type | 1.05 | 1.03 | 1.22 | 0.39 | 0.47 | 0.78 | 1.26 × 10−8 |
| ENOA | Alpha-enolase | 1.02 | 1.13 | 1.08 | 0.25 | 0.49 | 0.58 | 1.93 × 10−8 |
| ACOC | Cytoplasmic aconitate hydratase | 1.16 | 1.12 | 1.37 | 0.38 | 0.63 | 0.84 | 1.26 × 10−7 |
| PFKAP | ATP-dependent 6-phosphofructokinase platelet type | 1.01 | 1.06 | 1.18 | 0.34 | 0.46 | 0.70 | 2.83 × 10−7 |
| IDH3A | Isocitrate dehydrogenase [NAD] subunit alpha | 1.00 | 0.78 | 1.02 | 0.22 | 0.44 | 0.57 | 2.99 × 10−7 |
| PGP | Glycerol-3-phosphate phosphatase | 0.97 | 1.11 | 1.12 | 0.19 | 0.40 | 0.71 | 1.86 × 10−6 |
| ODPB | Pyruvate dehydrogenase E1 component subunit beta mitochondrial | 1.14 | 0.71 | 1.12 | 0.27 | 0.56 | 0.47 | 7.91 × 10−6 |
| IDH3B | Isocitrate dehydrogenase [NAD] subunit beta | 1.09 | 1.03 | 1.14 | 0.37 | 0.79 | 0.77 | 8.67 × 10−6 |
| ALDOC | Fructose-bisphosphate aldolase C | 1.03 | 1.28 | 1.25 | 0.49 | 1.07 | 1.09 | 2.17 × 10−5 |
| MAOX | NADP-dependent malic enzyme | 0.82 | 0.86 | 0.93 | 0.46 | 0.53 | 0.73 | 2.48 × 10−4 |
Color shading indicates to a value that has been downregulated or upregulated by 1.5 times or more. 1. 5 ≤ light green < 2.0, 2.0 ≤ green < 2.5, and 2.5 ≤ dark green for downregulation, and 1.5 ≤ light pink < 2.0 for upregulation.
List of upregulated proteins from control and SiO2 NP groups of HepG2 cells by the exposure time associated with the biological pathway.
| Protein | Description | Fold Change Compared to 0 h Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Control (h) | SiO2 NPs (h) | |||||||
| 4 | 10 | 16 | 4 | 10 | 16 | |||
|
| ||||||||
| CD81 | CD81 antigen | 1.04 | 1.31 | 1.24 | 2.92 | 4.84 | 6.26 | 1.27 × 10−9 |
| EGFR | Epidermal growth factor receptor | 0.97 | 1.28 | 1.11 | 1.18 | 1.91 | 2.13 | 1.41 × 10−9 |
| ANTR1 | Anthrax toxin receptor 1 | 1.02 | 1.12 | 1.00 | 1.72 | 2.48 | 3.09 | 3.94 × 10−8 |
| FOLR1 | Folate receptor alpha | 0.59 | 1.02 | 1.27 | 1.08 | 2.20 | 2.78 | 5.87 × 10−8 |
| FLOT2 | Flotillin-2 | 1.62 | 1.26 | 0.57 | 0.89 | 1.56 | 2.93 | 8.51 × 10−7 |
| A4 | Amyloid-beta precursor protein | 0.87 | 0.87 | 0.99 | 1.37 | 2.07 | 1.83 | 1.45 × 10−6 |
| TXND5 | Thioredoxin domain-containing protein 5 | 0.94 | 1.70 | 1.49 | 1.82 | 2.23 | 2.01 | 1.62 × 10−6 |
| LG3BP | Galectin-3-binding protein | 1.07 | 1.31 | 1.44 | 1.27 | 2.03 | 2.49 | 2.01 × 10−6 |
| B2MG | Beta-2-microglobulin | 1.06 | 1.24 | 1.38 | 1.62 | 1.98 | 2.23 | 2.81 × 10−6 |
|
| ||||||||
| HLAA | HLA class I histocompatibility antigen A alpha chain | 0.94 | 1.20 | 1.22 | 1.25 | 2.23 | 2.01 | 1.36 × 10−7 |
| ITB1 | Integrin beta-1 | 1.06 | 1.15 | 1.22 | 0.75 | 1.90 | 2.39 | 3.53 × 10−7 |
| ITAV | Integrin alpha-V | 1.07 | 1.29 | 1.49 | 1.00 | 1.43 | 2.24 | 3.72 × 10−7 |
| S61A1 | Protein transport protein Sec61 subunit alpha isoform 1 | 1.00 | 1.33 | 1.48 | 0.64 | 1.19 | 2.38 | 2.94 × 10−6 |
| VA0D1 | V-type proton ATPase subunit d 1 | 1.02 | 1.63 | 1.28 | 0.94 | 1.94 | 2.16 | 1.81 × 10−5 |
|
| ||||||||
| OST48 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit | 0.88 | 1.42 | 1.23 | 2.11 | 2.84 | 3.07 | 2.08 × 10−10 |
| CATA | Catalase | 1.02 | 1.26 | 1.32 | 1.02 | 1.80 | 2.18 | 3.15 × 10−10 |
| GNS | N-acetylglucosamine-6-sulfatase | 0.97 | 1.39 | 1.75 | 0.71 | 1.82 | 2.56 | 1.04 × 10−8 |
| BST2 | Bone marrow stromal antigen 2 | 0.84 | 1.11 | 1.80 | 1.33 | 2.26 | 3.18 | 7.89 × 10−8 |
| HM13 | Minor histocompatibility antigen H13 | 0.95 | 1.24 | 1.19 | 1.40 | 2.11 | 2.42 | 1.06 × 10−7 |
| SQSTM | Sequestosome-1 | 0.86 | 0.75 | 0.61 | 1.18 | 2.16 | 2.70 | 2.33 × 10−7 |
| LAMP2 | Lysosome-associated membrane glycoprotein 2 | 1.07 | 1.64 | 1.80 | 1.51 | 2.56 | 3.12 | 2.09 × 10−6 |
| PCYOX | Prenylcysteine oxidase 1 | 1.12 | 1.26 | 1.40 | 2.35 | 2.50 | 2.40 | 3.10 × 10−6 |
| NICA | Nicastrin | 1.12 | 1.26 | 1.39 | 1.16 | 1.48 | 2.07 | 6.15 × 10−5 |
|
| ||||||||
| DEGS1 | Sphingolipid delta(4)-desaturase DES1 | 0.99 | 0.99 | 0.88 | 1.79 | 1.88 | 2.09 | 4.79 × 10−10 |
| ABCD3 | ATP-binding cassette sub-family D member 3 | 1.03 | 1.40 | 1.31 | 1.17 | 1.86 | 3.00 | 1.69 × 10−9 |
| MBOA7 | Lysophospholipid acyltransferase 7 | 0.86 | 1.18 | 1.02 | 1.95 | 2.05 | 2.11 | 9.06 × 10−9 |
| NCEH1 | Neutral cholesterol ester hydrolase 1 | 1.03 | 1.22 | 1.12 | 1.90 | 3.09 | 2.76 | 1.18 × 10−7 |
| CTL1 | Choline transporter-like protein 1 | 1.22 | 1.80 | 1.25 | 1.07 | 3.86 | 3.63 | 1.93 × 10−7 |
| ERLN2 | Erlin-2 | 0.80 | 1.21 | 0.75 | 1.03 | 1.99 | 2.03 | 3.21 × 10−7 |
| MGST3 | Microsomal glutathione S-transferase 3 | 0.86 | 1.88 | 1.46 | 1.64 | 2.13 | 1.98 | 8.53 × 10−7 |
| ACAD9 | Complex I assembly factor ACAD9 mitochondrial | 1.17 | 1.27 | 1.44 | 1.32 | 1.77 | 2.10 | 1.01 × 10−6 |
| GPAA1 | Glycosylphosphatidylinositol anchor attachment 1 protein | 1.09 | 1.03 | 0.67 | 3.12 | 2.96 | 3.06 | 1.05 × 10−6 |
| ACADM | Medium-chain specific acyl-CoA dehydrogenase mitochondrial | 1.19 | 1.44 | 1.43 | 2.53 | 1.62 | 1.64 | 1.79 × 10−6 |
| FDFT | Squalene synthase | 0.89 | 1.23 | 1.75 | 1.00 | 1.56 | 2.37 | 2.84 × 10−6 |
| ACOD | Acyl-CoA desaturase | 0.86 | 1.57 | 1.01 | 2.45 | 2.10 | 1.31 | 6.59 × 10−6 |
| HACL1 | 2-hydroxyacyl-CoA lyase 1 | 1.06 | 1.34 | 1.15 | 1.40 | 2.00 | 1.49 | 9.06 × 10−3 |
Color shading indicates to a value that has been downregulated or upregulated by 1.5 times or more. 1.5 ≤ light pink < 2.0, 2.0 ≤ pink < 2.5, and 2.5 ≤ red for upregulation, and 1.5 ≤ light green < 2.0 for downregulation.
Figure 6Representative MS and tandem MS spectra of downregulated (CDK1 and ACOC) and upregulated proteins (ACADM and LAMP2) in SiO2 NP-treated groups, which are involved in cell cycle checkpoint, carbon metabolism, lipid metabolism, and lysosome. Data were obtained using the software PEAKS Studio 10.5. (Abbreviations: CDK1, cyclin-dependent kinase 1; ACOC, cytoplasmic aconitate hydratase; ACADM, medium-chain specific acyl-CoA dehydrogenase mitochondrial; LAMP2, lysosome-associated membrane glycoprotein 2).
Figure 7Mechanisms of SiO2 NP-induced cytotoxicity in HepG2 cells. The order of biological reactions that occur when SiO2 NPs are exposed to cells is indicated by arrows. Orange, 4 h; red, 10 h; brown, 16 h; black, after 16 h. Responses observed in this study are indicated in bold letters, and those described through reference studies are indicated in light letters.